Procto-glivenol

LEAFLET INCLUDED IN THE PACKAGING: INFORMATION FOR THE PATIENT

Warning! Keep the leaflet, the information on the immediate packaging is in a foreign language!

Procto-Glyvenol

400 mg + 40 mg, suppositories

Tribenoside + Lidocaine

You should carefully read the contents of the leaflet before using the medicine because it contains important information for the patient.

This medicine should always be used exactly as described in the patient leaflet or as directed by your doctor or pharmacist.

• You should keep this leaflet, so you can read it again if you need to.
• If you need advice or additional information, you should consult a pharmacist.
• If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should tell their doctor or pharmacist. See section 4.
• If there is no improvement or the patient feels worse after 7 days, they should contact their doctor.

Table of contents of the leaflet

• 1. What is Procto-Glyvenol and what is it used for
• 2. Important information before using Procto-Glyvenol
• 3. How to use Procto-Glyvenol
• 4. Possible side effects
• 5. How to store Procto-Glyvenol
• 6. Contents of the packaging and other information

1. What is Procto-Glyvenol and what is it used for

Procto-Glyvenol in the form of suppositories is a medicine intended for the local treatment of external and internal hemorrhoids.
Tribenoside has anti-inflammatory, anti-edematous, analgesic, anti-itching effects, and also counteracts vascular endothelial damage.
Lidocaine is a local anesthetic and relieves symptoms caused by hemorrhoids, such as itching, burning, and pain.
Procto-Glyvenol in the form of suppositories acts locally, practically without systemic action.

2. Important information before using Procto-Glyvenol

When not to use Procto-Glyvenol:

• if the patient is allergic to tribenoside, lidocaine, or any of the other ingredients of this medicine (listed in section 6), or to other local anesthetics with an amide structure.

Warnings and precautions

Before starting to use Procto-Glyvenol in the form of suppositories in people with liver function disorders, this should be discussed with a doctor.
Procto-Glyvenol in the form of suppositories should be used with caution in patients with severe liver damage.
In addition to the treatment of hemorrhoids with Procto-Glyvenol, it is recommended to maintain proper hygiene of the anal area, use appropriate physical exercises, and use an appropriate diet to maintain a soft stool consistency.
This medicine should not be taken orally.
Eye contact should be avoided.

Children

This medicine should not be used in children because there are no data available on the safety of use in this age group.

Procto-Glyvenol and other medicines

No interactions with other medicines have been reported so far.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those that are available without a prescription.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
Procto-Glyvenol in the form of suppositories should not be used during the first 3 months of pregnancy.
Procto-Glyvenol in the form of suppositories may be used from the 4th month of pregnancy and during breastfeeding, provided that the recommended doses are not exceeded.

Driving and using machines

Procto-Glyvenol has no influence or negligible influence on the ability to drive and use machines.

3. How to use Procto-Glyvenol

This medicine should always be used exactly as described in the patient leaflet or as directed by your doctor or pharmacist. If you have any doubts, you should consult your doctor or pharmacist.
Rectal administration.
The recommended dose is 1 suppository in the morning and 1 suppository in the evening - until the acute symptoms disappear.
Then the dose can be reduced, using 1 suppository once a day.
The recommended doses of the medicine should not be exceeded.
Hands should be washed thoroughly after each use of the medicine.

Children

This medicine should not be used in children because there are no data available on the safety of use in this age group.

How long to use Procto-Glyvenol

Procto-Glyvenol in the form of suppositories should be used until the symptoms disappear.
If after 7 days of use there is no improvement or other, previously unobserved symptoms appear, the patient should consult their doctor to rule out other potential causes of these symptoms.

Using more than the recommended dose of Procto-Glyvenol

No cases of overdose with Procto-Glyvenol in the form of suppositories have been reported. There is no specific antidote for lidocaine.
Overdose should not occur when using the medicine according to the recommended dosage regimen.
In case of overdose, the patient should immediately consult their doctor.

Missing a dose of Procto-Glyvenol

A double dose should not be used to make up for a missed dose.

Stopping the use of Procto-Glyvenol

If you have any further doubts about the use of this medicine, you should consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
To evaluate side effects, the following frequency categories have been used:
Rare side effects(more than 1 person in 10,000, less than 1 person in 1,000):

• urticaria,
• itching at the site of administration, rash at the site of administration, pain at the site of administration.

Very rare side effects(may occur in up to 1 person in 10,000):

• anaphylactic reaction,
• cardiovascular disorders,
• bronchospasm,
• angioedema,
• facial edema.

Reporting side effects

If you experience any side effects, including any side effects not listed in the leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department for Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl

By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Procto-Glyvenol

The medicine should be stored out of sight and reach of children.
Store in a temperature below 30°C, in the original packaging.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the packaging and other information

What Procto-Glyvenol contains

• The active substances of the medicine are tribenoside and lidocaine. One suppository contains 400 mg of tribenoside and 40 mg of lidocaine.
• The other ingredients are: solid fat (Witepsol E85) and solid fat (Witepsol W35).

What Procto-Glyvenol looks like and what the packaging contains

Procto-Glyvenol is available in the form of suppositories with a conical shape - white to slightly yellowish.
Available packaging: 10 suppositories in PE-PP-Al blisters in a cardboard box.
To obtain more detailed information, you should contact the marketing authorization holder or the parallel importer.

Marketing authorization holder in Romania, the country of export:

RECORDATI ROMÂNIA S.R.L.
Str. Izvor nr. 92-96, Biroul B, camerele 2-8, Etaj 4
Sector 5, Bucharest
Romania

Manufacturer:

DELPHARM HUNINGUE SAS
26 rue de la Chapelle
68330 Huningue, France
ZETA FARMACEUTICI S.p.A.
Via Galvani, 10
36066 Sandrigo (VI), Italy
TEMMLER ITALIA S.R.L.
Via Delle Industrie
2-20061 Carugate (Mi), Italy

Parallel importer:

Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź

Repackaged by:

Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in Romania, the country of export: 7351/2015/01
Parallel import authorization number: 427/19

Date of leaflet approval: 02.10.2024

[Information about the trademark]